|Fresenius Medical Care AG Co KGAA -- USA Stock|| |
USD 108.83 0.16 0.15%
Member of the Management Board for Global Research & Development
Dr. Olaf Schermeier is Chief Executive Officer for Global Research and Development, Member of the Management Board at Fresenius Medical Care AG Co. KGaA since March 1, 2013. Previously, he served as president of global RD for Draeger Medical, Luebeck, Germany
Age: 43 Executive Since 2013 Ph.D
49 6172 609 0 http://www.fmc-ag.com
Schermeier has many years of experience in various areas of the health care industry, among others at Chariteclinic and Biotronik, Germany. He holds a doctorate degree in Computer Science from the Technische Universitaet Berlin and graduated from the University of Hannover in Electrical Engineering.
The company has return on total asset (ROA)
of 6.11 %
which means that it generated profit of $6.11 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 13.05 %
meaning that it generated $13.05 on every $100 dollars invested by stockholders.
The company has accumulated 9.22 B in total debt with debt to equity ratio (D/E) of 71.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Fresenius Medical Care AG Co KGAA has Current Ratio of 1.2 suggesting that it is not liquid enough and may have problems to pay out its financial obligations in time and when they become due.
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, offer dialysis treatment and related dialysis care services, and other health care services. Fresenius Medical Care AG Co KGAA (FMCQF) is traded on OTC Market in USA. It is located in Bad Homburg, and employs 108,851 people.